Update shared on16 Aug 2025
Fair value Decreased 5.12%The consensus analyst price target for Cohance Lifesciences has been revised downward, primarily reflecting a notable decline in net profit margin and a higher future P/E multiple, resulting in a new target of ₹1246.
What's in the News
- Board meeting scheduled to consider and approve unaudited financial results for the quarter ending June 30, 2025.
- The meeting will also address other unspecified matters.
Valuation Changes
Summary of Valuation Changes for Cohance Lifesciences
- The Consensus Analyst Price Target has fallen from ₹1313 to ₹1246.
- The Net Profit Margin for Cohance Lifesciences has significantly fallen from 29.75% to 24.58%.
- The Future P/E for Cohance Lifesciences has significantly risen from 52.95x to 61.65x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.